The Elevated blood pressure and elevated protein in the urine of pregnant women are categorized by preeclampsia, a speedily progressive situation. It is one of the hypertensive pregnancy syndromes that is accountable for accelerating the rate of maternal & prenatal morbidity and mortality in underdeveloped and emerging countries. It may lead to preterm birth and several other complications, such as seizures or eclampsia, organ failure, and death if not detected at an early stage. For instance, it has been assessed that pregnancy-induced hypertension is accountable for causing 76,000 maternal and 500,000 child fatalities international per year, according to the Preeclampsia Foundation.
According to the report analysis, ‘COVID-19 Impact on Global Preeclampsia Diagnostics Market by Test Type(Blood Test and Urine Analysis); By Product Type (Instruments and Consumables); By End User (Hospitals, Specialty Clinics, Diagnostic Centers and Others.) and Region –Analysis of Market Size, Share and Trends for 2014 – 2019 and Forecasts to 2030’ states that the Global Preeclampsia Diagnostics Market size was accountable at USD 1.07 billion during 2019 and is projected to reach USD 3.64 billion by 2030, accounting a CAGR of 11.92% from 2020 to 2030. Worldwide market growth in preeclampsia diagnostics is propelled mainly by augmenting the preeclampsia incidences globally. The growth of the market for preeclampsia diagnostics is projected to be propelled by the rapidly growing demand for its diagnosis and care. The augment in maternal & perinatal mortality and morbidity rates is also projected to increase the requirement amongst pregnant women for premature diagnosis of preeclampsia.
Furthermore, the effective augment in the awareness among healthcare professionals of the efficacious screening approaches for the condition and growing knowledge of the signs and symptoms linked with preeclampsia amongst pregnant mothers and are probable to fuel speedy growth in the requirement for preeclampsia diagnostics over the forecast duration.
Additionally, the worldwide pandemic COVID-19 has become worldwide stress, not just for human lives, but also for industries around dissimilar industry verticals. The COVID-19 syndrome has infected quite a few million people globally, with an accumulative number of active cases daily, the interval of the pandemic is still challenging to predict. The pandemic of coronavirus has stemmed in an unprecedented ultimatum for our health system. The intensification of COVID-19 cases has raised comprehensive concerns for older people, children, and pregnant women. Throughout these days, a substantial rise in preeclampsia testing was experimental due to the number of pregnancies throughout the lockout, postponed or canceled abortion cases owing to the lack of access to midwives or health care conveniences, and high risks accompanying the occurrence of preeclampsia amongst the pregnant women positive for COVID-19.
The lockdown would lead to 7 million premature pregnancies internationally, according to a report by UNICEF. Also, owing to the pervasiveness of proteinuria present in both conditions, there is an improved diagnostic problem associated with present COVID-19 cases and preeclampsia. Also, positive government help in the form of guideline amendments to deal with prenatal cases and preeclampsia management and continuing the accessibility of health care facilities amid loading on them would boost the requirement for preeclampsia screening during 2020. Although, the pharmaceutical corporates have dramatically strengthened their supply chain management, greater their R&D capabilities, and participated more in their production management and eminence control. Therefore, in the near years, it is anticipated that the market of preeclampsia diagnostic will increase around the globe more effectively over the forthcoming years.
For More Information on the Research Report, refer to below links: -
Ankur Gupta, Head Marketing & Communications